We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03624946
Recruitment Status : Completed
First Posted : August 10, 2018
Results First Posted : July 13, 2020
Last Update Posted : December 8, 2020
Sponsor:
Information provided by (Responsible Party):
Emergent BioSolutions

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic intervention against Zika virus infection. In this first-in-human study, evaluation of ZIKV-IG safety and pharmacokinetics (absorption, metabolism and excretion) will be conducted in healthy adult volunteers.

Condition or disease Intervention/treatment Phase
Zika Virus Infection Zika Virus Disease Biological: Zika Virus Immune Globulin (ZIKV-IG) Other: Placebo Phase 1

Detailed Description:

This study will be evaluating safety and pharmacokinetics (PK) of one dose level of ZIKV-IG (50 mL) in healthy adult volunteers. The study is a single-center, double-blind, randomized and placebo-controlled design. The primary objective is to assess safety of intravenously (IV) administered ZIKV-IG, while the secondary objective is to determine the PK profile of ZIKV-IG in healthy adult volunteers.

There will be a total of 30 subjects enrolled into the study; dosing of the first six subjects will be staggered over three separate days, wherein two subjects per day will be randomized 1:1 to either receive 50 mL of placebo IV or 50 mL of ZIKV-IG IV (the total amount of gamma immune globulin [IgG] protein from a single 50mL dose is 4.65g). After the first six subjects are dosed, the remaining 24 subjects will be randomized 2:1 to receive either ZIKV-IG or placebo. A safety monitoring committee will review safety data (collected up to 3 days post-dosing) of the first 12 dosed subjects prior to dosing of the remaining 18 subjects. Overall, there will be 19 subjects randomized to receive ZIKV-IG and 11 subjects randomized to receive placebo on Day 1. On Day 1 (post-dose at 1 hour, 3 hours, 8 hours) and Day 2, safety and PK assessments will be conducted while the subjects are in the Phase 1 clinic. After the discharge on Day 2, the subjects will come back to the clinic for safety and PK assessments on Days 3, 4, 6, 8, 10, 12, 15, 22, 29, 43, 57 and 85. Total study duration for each subject will be up to 4 months (from screening to Day 85).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers
Actual Study Start Date : June 27, 2018
Actual Primary Completion Date : March 6, 2019
Actual Study Completion Date : March 6, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Zika Virus Immune Globulin (ZIKV-IG)
Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
 Biological: Zika Virus Immune Globulin (ZIKV-IG)
Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
Other Names:
  • Anti-Zika Immune Globulin (Human)
  • NP-024
Placebo Comparator: Placebo (Saline Solution)
Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
 Other: Placebo
Placebo is a normal saline solution (0.9% sodium chloride).
Other Name: Saline solution


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Subjects With Adverse Events. [ Time Frame: Up to Day 85 ]
    Number of subjects with of adverse events by severity.


Secondary Outcome Measures :
  1. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax) [ Time Frame: 0-2 hours predose to Day 85 postdose ]
    Maximum observed serum concentration of Zika Virus Immune Globulin (ZIKV-IG)

  2. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax) [ Time Frame: 0-2 hours predose up to Day 85 postdose ]
    Time at which maximum serum concentration of Zika Virus Immune Globulin (ZIKV-IG) occurs.

  3. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t) [ Time Frame: 0-2 hours predose to Day 85 postdose ]
    Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration.

  4. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf) [ Time Frame: 0-2 hours predose up to Day 85 postdose ]
    Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration, plus the area extrapolated to infinity.

  5. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL) [ Time Frame: 0-2 hours predose up to Day 85 postdose ]
    Total body clearance of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.

  6. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2) [ Time Frame: 0-2 hours predose up to Day 85 postdose ]
    Apparent first order terminal elimination half-life of Zika Virus Immune Globulin (ZIKV-IG).

  7. Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz) [ Time Frame: 0-2 hours predose up to Day 85 postdose ]
    Volume of distribution of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed consent voluntarily signed by subject.
  2. Age: 18-55 years of age.
  3. Blood type O+ or O-.

  4. Body mass index (BMI) of 18-30.

    • Note: minimum body weight of 50 kg.

  5. For female subjects (with male partners) that are not surgically sterilized (e.g., did not undergo hysterectomy, bilateral oophorectomy or tubal ligation), use of an effective method of contraception throughout the trial including:

    • Using hormonal contraception (oral, injectable or implant) continuously for 3 months prior to screening and willing to continue to use hormonal contraception throughout the entire trial.
    • Intrauterine device (IUD) inserted at least 1 month prior to screening.
    • Double barrier type of birth control measure (e.g., condoms, diaphragms, cervical sponge with spermicide).
    • True abstinence.
    • For female subjects who are post-menopausal, documented follicle- stimulating hormone (FSH) ≥40 milli-international units per milliliter (mIU/mL) must be obtained. If the FSH is <40 mIU/mL, the subject must agree to use an acceptable form of contraception (see above).
    • Females of childbearing potential without male sexual partners must be willing to maintain their sexual status as it is throughout the study.

  6. For male subjects that have not had a vasectomy, use of a condom with spermicide or true abstinence for the duration of the study. Note: female partners (that are of childbearing potential) of male study subjects (that have not had a vasectomy) should use one of the effective contraception methods (eg, hormonal contraception, IUD or barrier type). Also, male subjects must not donate sperm for the duration of the study.

    • Males without female sexual partners must be willing to maintain their sexual status as it is throughout the study.
  7. Healthy as determined by principal investigator or a qualified designate based on medical history, physical exam, vital signs, urinalysis, blood chemistry and hematology test results at screening.

Exclusion Criteria:

  1. Use of any investigational product within the past 30 days.
  2. Use of any investigational product during the study.
  3. Individuals with blood type A, B or AB.
  4. Recipient of any blood product within the past 12 months.
  5. Plasma donation within 7 days or significant blood loss or blood donation within 56 days of baseline.
  6. Blood donation at any time during the study.
  7. Females with a hemoglobin level ≤120 g/L.
  8. Males with a hemoglobin level <130 g/L.
  9. History of hypersensitivity to blood or plasma products.
  10. History of allergy to latex or rubber.
  11. History of immunoglobulin A (IgA) deficiency.
  12. History of hypercoagulable conditions (e.g., deep vein thrombosis or pulmonary embolism).
  13. History of myocardial infarction.
  14. History of stroke.
  15. History of renal impairment/failure.
  16. Currently pregnant or lactating or planning to become pregnant during the study.
  17. History of flavivirus infection [ZIKV, dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV)] or vaccination with licensed or investigational flavivirus vaccine.
  18. Plans to travel to an area with active flavivirus (e.g., ZIKV and/or DENV) transmission during the study (and up to 10 months after the study drug administration) or has returned from an endemic area with these diseases within 30 days of screening.
  19. Positive nucleic acid test (NAT) or serology for ZIKV or positive serology for WNV or DENV.
  20. Positive serology test (at screening) for human immunodeficiency virus 1 and 2 (HIV), hepatitis C virus (HCV); positive test for hepatitis B virus (HBV) as determined by HBsAg.
  21. History of chronic or acute severe neurologic condition (e.g., diagnosis of Guillain-Barre syndrome, epilepsy, Bell's palsy, meningitis or disease with any focal neurologic deficits).
  22. Heavy smokers (≥15cigarettes a day) or electronic cigarette use.
  23. History of, or suspected substance abuse problem (including alcohol).
  24. Failure of drug (urine) test at screening or baseline.
  25. Failure of alcohol (breath) test at screening or baseline.
  26. Receipt of a live vaccine within 28 days prior to screening or anticipated receipt of a live vaccine during the study period.
  27. Individuals with planned surgical procedures that will occur during the study.
  28. An opinion of the investigator that it would be unwise to allow participation of the subject in the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03624946


Locations
Layout table for location information
Canada, Ontario
Syneos Health, Early Phase
Toronto, Ontario, Canada, M5V 2T3
Sponsors and Collaborators
Emergent BioSolutions
Investigators
Layout table for investigator information
Principal Investigator: Vadim Dreyzin, MD Syneos Health
Principal Investigator: Michael McDonnell, MD Syneos Health
  Study Documents (Full-Text)

Documents provided by Emergent BioSolutions:
Statistical Analysis Plan  [PDF] April 12, 2018
Study Protocol  [PDF] June 5, 2018

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT03624946    
Other Study ID Numbers: ZK-001
First Posted: August 10, 2018    Key Record Dates
Results First Posted: July 13, 2020
Last Update Posted: December 8, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Emergent BioSolutions:
Zika virus
Human immune globulin
Hyperimmune
Polyclonal antibodies
Additional relevant MeSH terms:
Layout table for MeSH terms
Zika Virus Infection
Virus Diseases
Infections
Arbovirus Infections
Vector Borne Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
 Immunoglobulins
Antibodies
gamma-Globulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs